Trial aims to extend remission for children treated with T-cell immunotherapy for leukemia – Medical Xpress
|
Trial aims to extend remission for children treated with T-cell immunotherapy for leukemia
Medical Xpress After phase 1 results of Seattle Children’s Pediatric Leukemia Adoptive Therapy (PLAT-02) trial have shown T-cell immunotherapy to be effective in getting 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) into … |
|
Trial aims to extend remission for children treated with T–cell immunotherapy for leukemia
EurekAlert (press release) The new phase 1 pilot study, PLAT-03, will examine the feasibility and safety of administering a second T-cell product intended to increase the long-term persistence of the patient’s chimeric antigen receptor (CAR) T cells that were reprogrammed to … |
|
Trial aims to extend remission for children treated with T–cell immunotherapy for leukemia
EurekAlert (press release) The new phase 1 pilot study, PLAT-03, will examine the feasibility and safety of administering a second T-cell product intended to increase the long-term persistence of the patient’s chimeric antigen receptor (CAR) T cells that were reprogrammed to … |
Medscape |
Avelumab: Another Immunotherapy for Bladder Cancer
Medscape Another immunotherapy has been approved for use in urothelial cancer, the most common type of bladder cancer, in the United States. Avelumab (Bavencio, EMD Serono INc), which is a programmed cell death ligand–1 (PD L1) inhibitor, has been approved … Avelumab Granted Accelerated Approval for Bladder CancerSpecialty Pharmacy Times |
|
mRCC Control Seen After Immunotherapy Is Stopped
Clinical Oncology News mRCC Control Seen After Immunotherapy Is Stopped. Orlando, Fla.—Patients with mRCC who respond to programmed death 1/programmed death ligand 1 checkpoint inhibitor therapy can have persistent clinical benefit, even after treatment discontinuation. |